FDA inspection
Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer, Inc.: FDA inspection ending Jul 27, 2017
FDA inspection 1019905 · Voluntary Action Indicated (VAI) · Rouses Point, NY
Key facts
| Inspection ID | 1019905 |
|---|---|
| Firm | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer, Inc. |
| FEI number | 1310337 |
| Address | 64 Maple St |
| City | Rouses Point |
| State | NY |
| ZIP | 12979 |
| Country | United States |
| Fiscal year | 2017 |
| Inspection end date | Jul 27, 2017 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data